Novartis in up to $2.9 billion licensing deal for PTC Therapeutics Huntington's disease drug
Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological disorder called Huntington's disease, sending the U.S.-based biotech's shares up about 14% on Monday.
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
On Monday, PTC Therapeutics, Inc. (NASDAQ:PTCT) signed an exclusive global license and collaboration agreement with Novartis AG (NYSE:NVS) for its PTC518 Huntington’s disease program, which includes related molecules.
Novartis and PTC Therapeutics link to develop Huntington’s therapy
Novartis has entered a worldwide licensing and partnership agreement with PTC Therapeutics to develop PTC518, a potential oral therapy for Huntington's disease (HD). The PTC518 Huntington's disease programme also encompasses related molecules.
Novartis pays PTC $1B upfront for midphase Huntington's program, reestablishing itself in R&D race
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping the biotech bounce quickly back from disappointing data on another program.
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js
Novartis to pay $1 billion upfront to license Huntington’s drug from PTC
Novartis is paying $1 billion upfront in a licensing deal for an experimental Huntington’s disease treatment from PTC Therapeutics.
PTC Therapeutics boosted by Novartis rights deal for Huntington’s program
The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS program.
Novartis signs licensing deal worth up to $2.9B with PTC Therapeutics
The Swiss pharmaceutical company invests in a PTC Therapeutics program to develop treatment for Huntington’s disease.
Novartis Pays Up to $2.9B in Huntington’s Deal With PTC
Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing Phase II data in amyotrophic lateral sclerosis.
Novartis, PTC Ink Up-to-$2.9B Huntington’s Disease Collaboration
Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license and collaboration agreement.
PTC Therapeutics Partners with Novartis for Huntington’s Program
PTC Therapeutics ( ) has provided an announcement. PTC Therapeutics has entered a significant collaboration with Novartis for its PTC518 Huntington’s disease program, set to rec
Stocktwits on MSN21h
PTC Therapeutics Stock Eyes Further Rally After Price-Target Hikes On Huntington’s Therapy Deal With Novartis: Retail Buzz Grows
Shares of PTC Therapeutics Inc. climbed nearly 1% pre-market Tuesday, poised to extend their rally to levels last seen in ...
PTC Therapeutics price target raised to $71 from $47 at UBS
UBS raised the firm’s price target on PTC Therapeutics (PTCT) to $71 from $47 and keeps a Buy rating on the shares. PTC Therapeutics on Monday ...